Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer

Phase 4

Completed

• Conditions: Cancer
• Interventions: Drug: dalteparin

• Registration Number: NCT00942968
• Lead Sponsor: Pfizer

Brief Summary

The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-06
• Study First Submitted: 2009-07-16
• Study First Submitted QC: 2009-07-20
• Study First Posted: 2009-07-21
• Primary Completion: 2012-03
• Study Completion: 2013-06
• Results First Submitted: 2017-01-04
• Results First Submitted QC: 2017-01-04
• Results First Posted: 2017-02-24
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-16
• Last Update Posted: 2024-04-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 338

Inclusion Criteria

1. Male and female subjects, age greater than or equal to 18 years of age.
2. Females should be either of non-childbearing potential as a result of surgery, radiation therapy, menopause (one year post onset), or of childbearing potential and willing to adhere to an acceptable method of pregnancy prevention.
3. Subjects must be newly diagnosed, symptomatic proximal deep-vein thrombosis of the lower extremity, pulmonary embolism, or both.
4. Subjects must have active malignancy defined as a diagnosis of cancer (excluding basal cell or squamous cell carcinoma of the skin) within six months before enrollment, having received any treatment for cancer within the previous six months, or having documented recurrent or metastatic cancer.
5. Prior to enrollment, subjects must not have received therapeutic doses of anticoagulant therapy (including low molecular weight heparin [LMWH]) for >48 hours (or >4 doses within 48 hours).
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
7. Subjects must have a life expectancy of >6 months.
8. Subjects must have a platelet count of >75,000 mm^3.
9. The subject must not be on any oral anticoagulant therapy for concomitant diseases.
10. Subjects must have no active or serious bleeding episodes within two weeks prior to study entry.
11. Subjects must be able to comply with scheduled follow-ups.

Exclusion Criteria

1. Subjects who have a high risk of serious bleeding (e.g., recent neurosurgery within 30 days, history of intracranial hemorrhage, acute gastroduodenal ulcer, etc.).
2. Subjects who are on hemodialysis.
3. Subjects who have a prior placement of a Greenfield filter or other device to prevent embolization of deep vein thromboses.
4. Subjects with a known contraindication to the use of heparin (e.g., heparin-induced thrombocytopenia).
5. Subjects with a known hypersensitivity to heparin, dalteparin sodium, other LMWHs or pork products.
6. Subjects who are currently participating in another clinical trial involving anticoagulation therapy (with the exception of acetylsalicylic acid (ASA) in the 30 days prior to study entry, or who are actively using any investigational drugs/treatments 30 days prior to study entry involving anticoagulation therapy (with the exception of ASA , t.i.d).
7. Subject is pregnant or breast feeding.
8. Subjects with uncontrolled hypertension characterized by a sustained systolic pressure >170 mmHg and/or diastolic pressure >100 mmHg.
9. Subjects with a serious concomitant systemic disorder (for example, active infection including HIV or cardiac disease) that in the opinion of the investigator, would compromise the subject's ability to complete the study.
10. Any condition that makes the subject unsuitable in the opinion of the investigator.
11. Subjects with leukemia or myeloproliferative syndrome.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	dalteparin	-

Primary Outcome Measures

Name	Time	Method
Number of Participants With Major Bleeding Events Adjudicated by Central Adjudication Committee	Month 7 up to Month 12	A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: 1) bleeding accompanied by a decrease in hemoglobin of \>=2 g/dL, 2) bleeding occurred at a critical site (intraocular, spinal/epidural, intracranial, retroperitoneal, or pericardial bleeding), 3) bleeding leads to a transfusion of two or more units of packed red blood cells, 4) bleeding leads to death. In this outcome measure, number of participants with major bleeding events (adjudicated by Central Adjudication Committee) were reported.
Number of Participants With New or Recurrent Venous Thromboembolism (VTE) Adjudicated by Central Adjudication Committee	Month 7 up to Month 12	VTEs included both deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is a blood clot in the deep veins of the leg. If a DVT clot breaks off (embolizes) from a vein wall and flows towards the lungs and blocks some or all of the blood supply, it becomes pulmonary embolism (PE). When a blood clot (thrombus) breaks, loose and travels in the blood, this is called a venous thromboembolism. DVT was diagnosed using either computed tomography scan or contrast venography. PE was diagnosed by either radionuclide ventilation-perfusion studies, contrast CT scan or an angiogram. In this outcome measure, number of participants with new or recurrent VTE (adjudicated by Central Adjudication Committee) were reported.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Any Bleeding Event (Major or Minor) Adjudicated by Central Adjudication Committee	Month 1 up to Month 6, Month 7 up to Month 12, Month 1 up to Month 12, Month 2 up to Month 6, and Month 2 up to Month 12	A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: 1) bleeding accompanied by a decrease in hemoglobin of \>=2 g/dL, 2) bleeding occurred at a critical site (intraocular, spinal/epidural, intracranial, retroperitoneal, or pericardial bleeding), 3) bleeding leads to a transfusion of two or more units of packed red blood cells, 4) bleeding leads to death. A bleeding event was considered as minor if it was clinically overt but not meeting the criteria for major bleeding. In this outcome measure, number of participants with any (major or minor) bleeding events (adjudicated by Central Adjudication Committee) were reported.
Number of Participants With Investigator Identified Major Bleeding Events	Month 1 up to Month 6; Month 7 up to Month 12; Month 1 up to Month 12; Month 2 up to Month 6; Month 2 up to Month 12	A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: 1) bleeding accompanied by a decrease in hemoglobin of \>=2 g/dL, 2) bleeding occurred at a critical site (intraocular, spinal/epidural, intracranial, retroperitoneal, or pericardial bleeding), 3) bleeding leads to a transfusion of two or more units of packed red blood cells, 4) bleeding leads to death. In this outcome measure, number of participants with major bleeding events (identified by investigator) were reported.
Number of Participants With Fatal Bleeding Events	Month 1 up to Month 6; Month 7 up to Month 12; Month 1 up to Month 12; Month 2 up to Month 6; Month 2 up to Month 12	Fatal bleeding events refers to those bleeding events which leads to death of participant. In this outcome measure, number of participants with fatal bleeding events were reported.
Time to First Occurrence of Major Bleeding Event Adjudicated by Central Adjudication Committee	Month 1 up to Month 12	Time to first occurrence of major bleeding event was defined as the time interval (in days) between the date of first study treatment and the date of documentation of first major bleeding event. A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: 1) bleeding accompanied by a decrease in hemoglobin of \>=2 g/dL, 2) bleeding occurred at a critical site (intraocular, spinal/epidural, intracranial, retroperitoneal, or pericardial bleeding), 3) bleeding leads to a transfusion of two or more units of packed red blood cells, 4) bleeding leads to death.
Number of Participants With Investigator Identified New or Recurrent Venous Thromboembolism (VTEs)	Month 1 up to Month 6; Month 7 up to Month 12; Month 1 up to Month 12; Month 2 up to Month 6; Month 2 up to Month 12	VTEs included both DVT and PE. DVT is a blood clot in the deep veins of the leg. If a DVT clot breaks off (embolizes) from a vein wall and flows towards the lungs and blocks some or all of the blood supply, it becomes PE. When a blood clot (thrombus) breaks, loose and travels in the blood, this is called a venous thromboembolism. DVT was diagnosed using either computed tomography scan or contrast venography. PE was diagnosed by either radionuclide ventilation-perfusion studies, contrast CT scan or an angiogram. In this outcome measure, number of participants with new or recurrent VTE (identified by investigator) were reported.
Number of Participants With Investigator Identified New or Recurrent Venous Thromboembolism (VTE) or Central Venous Thrombosis (CVT)	Month 1 up to Month 6; Month 7 up to Month 12; Month 1 up to Month 12; Month 2 up to Month 6; Month 2 up to Month 12	VTEs included both DVT and PE. DVT is a blood clot in the deep veins of the leg. If a DVT clot breaks off (embolizes) from a vein wall and flows towards the lungs and blocks some or all of the blood supply, it becomes PE. When a blood clot (thrombus) breaks, loose and travels in the blood, this is called a venous thromboembolism. DVT was diagnosed using either computed tomography scan or contrast venography. PE was diagnosed by either radionuclide ventilation-perfusion studies, contrast CT scan or an angiogram. CVT is blood clot of the venous channels in the brain. CVT was diagnosed by contrast venography or ultrasonography. In this outcome measure, number of participants with new or recurrent VTE or CVT (identified by investigator) were reported.
Time to First Occurrence of New or Recurrent Venous Thromboembolism (VTE) Adjudicated by Central Adjudication Committee	Month 1 up to Month 12	Time to first occurrence of new or recurrent VTE was defined as the time interval (in days) between the date of first study treatment and the date of documentation of first VTE. VTEs included both DVT and PE. DVT is a blood clot in the deep veins of the leg. If a DVT clot breaks off (embolizes) from a vein wall and flows towards the lungs and blocks some or all of the blood supply, it becomes PE. When a blood clot (thrombus) breaks, loose and travels in the blood, this is called a venous thromboembolism. DVT was diagnosed using either computed tomography scan or contrast venography. PE was diagnosed by either radionuclide ventilation-perfusion studies, contrast CT scan or an angiogram.
Time to First Occurrence of Any Bleeding Event (Major or Minor) Adjudicated by Central Adjudication Committee	Month 1 up to Month 12	Time to first occurrence of any bleeding event was defined as the time interval (in days) between the date of first study treatment and the date of documentation of first bleeding event (major or minor). A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: 1) bleeding accompanied by a decrease in hemoglobin of \>=2 g/dL, 2) bleeding occurred at a critical site (intraocular, spinal/epidural, intracranial, retroperitoneal, or pericardial bleeding), 3) bleeding leads to a transfusion of two or more units of packed red blood cells, 4) bleeding leads to death. A bleeding event was considered as minor if it was clinically overt but not meeting the criteria for major bleeding.
Time to First Occurrence of New or Recurrent VTE or CVT Adjudicated by Central Adjudication Committee	Month 1 up to Month 12	Time to first occurrence of new or recurrent VTE or CVT was defined as the time interval (in days) between the date of first study treatment and the date of documentation of first VTE or CVT. VTEs included both deep vein thrombosis (DVT) and pulmonary embolism (PE) .DVT is a blood clot in the deep veins of the leg. If a DVT clot that breaks off (embolizes) from a vein wall and flows towards the lungs and blocks some or all of the blood supply, it becomes pulmonary embolism (PE). When a blood clot (thrombus) breaks, loose and travels in the blood, this is called a venous thromboembolism. DVT was diagnosed using either computed tomography scan, contrast venography or contrast venography. PE was diagnosed by either radionuclide ventilation-perfusion studies, contrast CT scan or an angiogram. CVT is blood clot of the venous channels in the brain. CVT was diagnosed by contrast venography or ultrasonography.
Number of Participants With New or Recurrent Venous Thromboembolism (VTE) or Central Venous Thrombosis (CVT) Adjudicated by Central Adjudication Committee	Month 1 up to Month 6; Month 7 up to Month 12; Month 1 up to Month 12; Month 2 up to Month 6; Month 2 up to Month 12	VTEs included both DVT and PE. DVT is a blood clot in the deep veins of the leg. If a DVT clot breaks off (embolizes) from a vein wall and flows towards the lungs and blocks some or all of the blood supply, it becomes PE. When a blood clot (thrombus) breaks, loose and travels in the blood, this is called a venous thromboembolism. DVT was diagnosed using either computed tomography scan or contrast venography. PE was diagnosed by either radionuclide ventilation-perfusion studies, contrast CT scan or an angiogram. CVT is blood clot of the venous channels in the brain. CVT was diagnosed by contrast venography or ultrasonography. In this outcome measure, number of participants with new or recurrent VTE or CVT (adjudicated by Central Adjudication Committee) were reported.

Trial Locations

Locations (42)

University Health Network-Toronto General Hospital; 🇨🇦 Toronto, Ontario, Canada

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

Bay Area Cancer Research Group; 🇺🇸 Pleasant Hill, California, United States

Harbor-UCLA Medical Center; 🇺🇸 Torrance, California, United States

Orchard Healthcare Research Inc.; 🇺🇸 Skokie, Illinois, United States

Atlanta Institute for Medical Research; 🇺🇸 Decatur, Georgia, United States

Halifax Health; 🇺🇸 Daytona Beach, Florida, United States

James Graham Brown Cancer Center; 🇺🇸 Louisville, Kentucky, United States

Bringham and Women's Hospital; 🇺🇸 Boston, Massachusetts, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

Stony Brook University, Medical Center; 🇺🇸 Stony Brook, New York, United States

Pennsylvania Oncology Hematology Associates; 🇺🇸 Philadelphia, Pennsylvania, United States

MidDakota Clinic; 🇺🇸 Bismarck, North Dakota, United States

Vermont Cancer Center at Fletcher Allen Health Care; 🇺🇸 Burlington, Vermont, United States

Medizinische Universitat Innsbruck Studienambulanz Hamatologie; 🇦🇹 Innsbruck, Austria

University of Virginia; 🇺🇸 Charlottesville, Virginia, United States

KH d. Elizabethinen Linz GmbH Servicestelle fur klin. Studien und Universitare Angelegenheiten; 🇦🇹 Linz, Austria

KH der Barmherzigen Schwestern; 🇦🇹 Linz, Austria

Dialysestation Landesklinkum St.Poelten; 🇦🇹 St. Poelten, Austria

Medizinische Universitat Wien; 🇦🇹 Vienna, Austria

University of Alberta; 🇨🇦 Edmonton, Alberta, Canada

London Health Sciences Centre; 🇨🇦 London, Ontario, Canada

Maisonneuve-Rosemont Hospital; 🇨🇦 Montreal, Quebec, Canada

Ottawa Health Research Institute; 🇨🇦 Ottawa, Ontario, Canada

Hospital General Santa Maria del Rosell; 🇪🇸 Caragena (Murcia), Spain

Hospital Virgen de la Arrixaca; 🇪🇸 El Palmar (Murcia), Spain

Hospital clinic i Provincial de Agencia de Ensayos Clinicos; 🇪🇸 Barcelona, Spain

Hospital Universitari Dr Josep Trueta; 🇪🇸 Girona, Spain

University of Rochester Medical Center; 🇺🇸 Rochester, New York, United States

Eastern Connecticut Hematology and Oncology Associates; 🇺🇸 Norwich, Connecticut, United States

Georgetown University Hospital-Lombardi Cancer Ctr; 🇺🇸 Washington, District of Columbia, United States

University of CT Health Center; 🇺🇸 Farmington, Connecticut, United States

Arizona Cancer Center; 🇺🇸 Tucson, Arizona, United States

LKH Graz Univrsitatstklinik fur Innere Medizin; 🇦🇹 Graz, Austria

Sir Mortimer B. Davis Jewish General Hospital; 🇨🇦 Montreal, Quebec, Canada

Orbis Medisch Centrum, Sittard-Geleen; 🇳🇱 Sittard-Geleen, Netherlands

Vancouver General Hospital; 🇨🇦 Vancouver, British Columbia, Canada

Gelre Ziekenhuizen-Locatie Apeldoorn; 🇳🇱 Apeldoorn, Netherlands

Henry Ford Hospital K-15; 🇺🇸 Detroit, Michigan, United States

University of Utah; 🇺🇸 Salt Lake City, Utah, United States

Clinica Universitaria de Navarra; 🇪🇸 Pamplona, Spain

Queen Elizabeth II Health Sciences Centre; 🇨🇦 Halifax, Nova Scotia, Canada